Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/toxins7114442 http://scihub22266oqcxt.onion/10.3390/toxins7114442 C4663513!4663513 !26529014     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26529014 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Toxins+(Basel) 2015 ; 7 (11 ): 4442-54 Nephropedia Template TP {{tp|p=26529014 |t=2015. Acupoint injection of onabotulinumtoxin A for migraines |pdf=|usr=}}{{26529014 }} gab.com Text Acupoint injection of onabotulinumtoxin A for migraines JO: Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=26529014 #FOAvip Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines. Twit Text FOAVip Acupoint injection of onabotulinumtoxin A for migraines ????Toxins (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=26529014 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26529014 #FOAvip English Wikipedia <ref>{{Cite pmid|26529014 }}</ref> Acupoint injection of onabotulinumtoxin A for migraines #MMPMID26529014 Hou M ; Xie JF ; Kong XP ; Zhang Y ; Shao YF ; Wang C ; Ren WT ; Cui GF ; Xin L ; Hou YP Toxins (Basel) 2015[Oct]; 7 (11 ): 4442-54 PMID26529014 show ga Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines. |*Acupuncture Points [MESH] |Adolescent [MESH] |Adult [MESH] |Botulinum Toxins, Type A/*administration & dosage/adverse effects/*therapeutic use [MESH] |Double-Blind Method [MESH] |Facial Muscles [MESH] |Female [MESH] |Humans [MESH] |Injections [MESH] |Injections, Intramuscular [MESH] |Male [MESH] |Middle Aged [MESH] |Migraine Disorders/*drug therapy/psychology [MESH] |Neuromuscular Agents/*administration & dosage/adverse effects/*therapeutic use [MESH] |Pain Measurement [MESH] |Treatment Outcome [MESH]Acupoint injection of onabotulinumtoxin A for migraines (epmc).pdf DeepDyve Pubget Overpricing